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OnabotulinumtoxinA 100U provides significant
improvements in overactive bladder symptoms in
patients with urinary incontinence regardless of the
number of anticholinergic therapies used or reason for
inadequate management of overactive bladder
K.-D. Sievert,1 C. Chapple,2 S. Herschorn,3 M. Joshi,4 J. Zhou,5 C. Nardo,4 V. W. Nitti6
SUMMARY
Introduction: A prespecified pooled analysis of two placebo-controlled, phase 3
trials evaluated whether the number of prior anticholinergics used or reason for
their discontinuation affected the treatment response to onabotulinumtoxinA 100U
in overactive bladder (OAB) patients with urinary incontinence (UI). Methods:
Patients with symptoms of OAB received intradetrusor injections of onabotulinum-
toxinA 100U or placebo, sparing the trigone. Change from baseline at week 12 in
UI episodes/day, proportion of patients reporting a positive response (‘greatly
improved’ or ‘improved’) on the treatment benefit scale (TBS), micturition and
urgency were evaluated by number of prior anticholinergics (1, 2 or ≥ 3) and rea-
son for their discontinuation (insufficient efficacy or side effects). Adverse events
(AE) were assessed. Results: Patients had taken an average of 2.4 anticholiner-
gics before study enrolment. OnabotulinumtoxinA reduced UI episodes/day from
baseline vs. placebo, regardless of the number of prior anticholinergics (2.82 vs.
1.52 for one prior anticholinergic; 2.58 vs. 0.58 for two prior anticholiner-
gics; and 2.92 vs. 0.73 for three or more prior anticholinergics; all
p < 0.001). The proportion of TBS responders was higher with onabotulinumtoxinA
vs. placebo (69.0% vs. 37.2% for one prior anticholinergic; 58.8% vs. 24.8% for
two prior anticholinergics and 56.4% vs. 22.5% for three or more prior anticholin-
ergics; all p < 0.001). Similar results were observed regardless of the reason for
discontinuation. OnabotulinumtoxinA reduced the episodes of urgency and fre-
quency of micturition vs. placebo in all groups. AEs were well tolerated, with a
comparable incidence in all groups. Conclusion: In patients with symptoms of
OAB who were inadequately managed by one or more anticholinergics, onabotuli-
numtoxinA 100U provided significant and similar treatment benefit and safety
profile regardless of the number of prior anticholinergics used or reason for inade-
quate management of OAB. ClinicalTrials.gov: NCT00910845, NCT00910520.
What’s known
• Anticholinergics are the first-line pharmacotherapy
for overactive bladder (OAB) and have been
shown to reduce the symptoms of OAB and
improve patients’ health-related quality of life.
However, many patients discontinue their use due
to insufficient efficacy or intolerable side effects.
• Two large, randomised, placebo-controlled, phase 3
studies demonstrated that onabotulinumtoxinA
100U significantly decreases urinary incontinence
(UI) episodes and improves patient perception of
treatment, compared with placebo, in OAB
patients with UI who have been inadequately
managed by anticholinergic therapies.
• In a study comparing the efficacy of
onabotulinumtoxinA with anticholinergic therapy,
patients treated with onabotulinumtoxinA 100U
were twice as likely as those receiving an
anticholinergic regimen to report complete
resolution of incontinence episodes.
What’s new
• Regardless of the number of prior
anticholinergics used or reason for their
discontinuation, treatment with
onabotulinumtoxinA 100U significantly reduced
UI, urgency episodes and micturition frequency,
which was reflected in patients’ positive
perception of treatment benefit.
• Results of the subgroup analyses were similar to
the significant and clinically relevant
improvements seen in the overall pooled
population.
• OnabotulinumtoxinA was well tolerated, with no
clinically relevant differences in the incidence of
adverse events between the overall pooled
population and the subgroups.
Introduction
Overactive bladder (OAB) is a chronic symptom
complex affecting 12–17% of the general population
(1–3), and is characterised by urgency, with or with-
out urinary urgency incontinence (UUI) usually
with increased daytime frequency and nocturia (4).
Urinary incontinence (UI) and other associated
1246
ª 2014 The Authors. International Journal of Clinical Practice published by John Wiley & Sons Ltd.
Int J Clin Pract, October 2014, 68, 10, 1246–1256. doi: 10.1111/ijcp.12443
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
1Department of Urology,
University of Tuebingen,
Tuebingen, Germany
2Department of Urology, Royal
Hallamshire Hospital, Sheffield,
UK
3Department of Urology,
University of Toronto, Toronto,
ON, Canada
4Allergan, Inc., Irvine, CA, USA
5Allergan, Inc., Bridgewater, NJ,
USA
6Department of Urology and
Obstetrics and Gynecology,
New York University Langone
Medical Center, New York, NY,
USA
Correspondence to:
Prof. Karl-Dietrich Sievert, PhD,
FACS, FRCS,
Vice Chair, Professor of
Urology, Director-Uro-oncology,
Neurourology, Incontinence,
and Reconstructive Urology,
Eberhard-Karls-University,
Department of Urology,
University of Tuebingen,
Hoppe-Seyler-Strasse 3, D72076
Tuebingen, Germany
Tel.: +49 7071 298 6611
Fax: +49 7071 295092
Email: karl.sievert@med.
uni-tuebingen.de;
kd_sievert@hotmail.com
Disclosures
Dr Sievert is a consultant,
lecturer and trial investigator
for Allergan, Inc., Astellas,
AMS, Medtronic and Neotract;
is a consultant for Janssen; and
a lecturer and a trial
investigator for Karl Storz Dr
Chapple is a consultant for
AMS, Lilly and ONO; and is a
consultant, researcher, speaker
and a trial investigator for
Allergan, Inc., Astellas, Pfizer
and Recordati. Dr Herschorn is
a consultant and trial
symptoms of OAB can be debilitating for affected
patients and may have a profound negative effect on
patients’ health-related quality of life (5,6). In addi-
tion, urgency is rated by patients in some studies as
the most bothersome of all symptoms, causing dis-
tress, embarrassment, loss of independence and dis-
ruption in their daily lives (7).
Anticholinergic agents are considered the mainstay
of pharmacologic therapy for OAB. Randomised
controlled trials of several anticholinergic therapies
have demonstrated clinical benefit, including
improvements in the symptoms of OAB and health-
related quality of life (8). However, up to 70% of
individuals discontinue anticholinergic therapy
within a year of initiation (9–12), most commonly
due to inadequate efficacy and/or intolerable side
effects (12). Patients who continue anticholinergic
therapy often have to try multiple anticholinergic
agents in succession (11).
Since OAB is a chronic symptom complex requir-
ing long-term therapy, there is a need for alternative
therapeutic options that are effective and could
potentially maximise the chance of treatment success
in patients who are inadequately managed by their
current therapy. OnabotulinumtoxinA is the only
botulinum toxin approved for the treatment of OAB
in patients, who have been inadequately managed by
≥ 1 anticholinergic therapy. Units of biological activ-
ity of onabotulinumtoxinA cannot be compared with
or converted into units of any other botulinum toxin
product, and onabotulinumtoxinA is not inter-
changeable with other botulinum toxin preparations.
Two large, double-blind, placebo-controlled,
phase 3 trials (13–15) showed that onabotulinum-
toxinA 100U significantly reduces all symptoms of
OAB, including episodes of incontinence, urgency,
micturition and nocturia compared with placebo.
Furthermore, 22.9% and 31.4% (15) of onabotuli-
numtoxinA-treated patients achieved complete conti-
nence at week 12 (i.e. 100% reduction in UI episodes)
in each of the trials (13,15), compared with only
6.5% and 10.3% of patients in the respective placebo
groups. Reductions in OAB symptoms were also
reflected in clinically meaningful improvements in
patients’ health-related quality of life.
Given the potential for cycling of patients on dif-
ferent anticholinergic regimens, and the high dis-
continuation rates for anticholinergics, it is
important to determine if onabotulinumtoxinA pro-
vides a similar clinical benefit and safety profile
regardless of the number of prior anticholinergics
used or the reason for their inadequate management
of OAB. This prespecified pooled analysis evaluated
the efficacy and safety of onabotulinumtoxinA in
the two following subgroups of patients: by the
number of prior anticholinergics used and by rea-
son for discontinuation of anticholinergic therapy.
Pooling the data from the two phase 3 trials
(13,14) provides a larger dataset for examination of
the efficacy and safety profile demonstrated in the
individual studies. The pooled data also allows for
further analyses of treatment response to onabotuli-
numtoxinA 100U in OAB patients with UI, who
had previously used one or more anticholinergics or
had discontinued their use due to inadequate effi-
cacy or intolerable side effects.
Methods
Study design
Details on the two phase 3 placebo-controlled trials
(NCT00910845 and NCT00910520) have been previ-
ously published (13,14). Briefly, patients with idio-
pathic OAB with three or more UUI episodes over a
3-day period and eight or more micturitions/day
were randomised 1 : 1 to receive 20 cystoscopic
intradetrusor injections (0.5 ml/injection) of onabo-
tulinumtoxinA 100U or placebo, sparing the trigone.
Patients were inadequately managed by one or
more anticholinergic (insufficient efficacy or intolera-
ble side effects); those with a predominance of stress
UI were excluded. The number of prior anticholiner-
gic therapies used and the reason for their inade-
quate management of OAB were recorded. Patients
participated in the study for 24 weeks unless they
withdrew consent or retreatment occurred. Retreat-
ment was with onabotulinumtoxinA, and could
occur from 12 weeks onward if the patient requested
it and had at least two UUI episodes over 3 days.
Therefore, the true placebo-controlled period was
12 weeks. The period between receipt of initial treat-
ment and retreatment or study exit (if no retreat-
ment) was defined as treatment cycle 1.
Efficacy and safety evaluations
A 3-day paper bladder diary was used to collect all
OAB symptoms (episodes of incontinence, urgency
and micturition). Patients recorded their perception
of treatment benefit at each posttreatment visit using
the treatment benefit scale (TBS), rating their condi-
tion as ‘greatly improved’, ‘improved’, ‘not changed’
or ‘worsened’. The number of prior anticholinergics
used and the reasons for inadequate management by
anticholinergic therapy were also recorded.
The coprimary end-points of change from baseline
at week 12 in UI episodes/day and proportion of
patients reporting a positive response (rating their
condition ‘greatly improved’ or ‘improved’) on the
TBS were evaluated in the overall pooled population
and in subgroups of patients by number of prior
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anticholinergic therapies (1, 2 or ≥ 3) and the pri-
mary reason for inadequate management by their
first anticholinergic therapy (insufficient efficacy or
intolerable side effects). Change from baseline in
urgency episodes and micturition frequency was also
assessed. The time to patient request for retreatment
was recorded for assessment of duration of treat-
ment.
Adverse events (AEs), postvoid residual (PVR)
urine volume and use of clean intermittent cathe-
terisation (CIC) were evaluated at weeks 2, 6 and
12 posttreatment or at any other time depending
on clinical need. CIC was initiated if the PVR
urine volume was ≥ 200 ml and < 350 ml with
associated symptoms (e.g. voiding difficulties or
sensation of bladder fullness) or if the PVR urine
volume was ≥ 350 ml, regardless of symptoms. The
AE of urinary retention was defined as a PVR
urine volume ≥ 200 ml that required CIC. The AE
of urinary tract infection (UTI) was defined as
positive urine culture with bacteriuria count of
> 105 colony-forming units/ml, together with leuko-
cyturia of > 5/high power field, even in the absence
of symptoms.
Statistical methods
Efficacy analyses were conducted using the overall
pooled intent-to-treat population (all randomised
patients) and safety analyses used the safety popula-
tion, which comprised all patients who received
treatment analysed by actual treatment received.
Daily UI episodes were analysed using an analysis
of covariance model, with baseline number of UI
episodes as covariates and study site and treatment
group as factors. TBS was analysed using the Coch-
ran-Mantel-Haenszel v2 method with the number of
baseline urgency UI episodes (≤ 9 or > 9) as a strati-
fication factor. Both phase 3 studies were planned to
provide 80% overall power to detect a between-
group difference in change from baseline in the co-
primary study end-points (a difference of 2.3 UI epi-
sodes/day, with a standard deviation of 8.5 for UI
and a between-group difference of 22% for TBS),
assuming an alpha of 0.05.
Results
Baseline demographics, disease characteristics
and anticholinergic profile
The overall pooled population comprised 1105
patients randomised to onabotulinumtoxinA 100U
(n = 557) or placebo (n = 548). Baseline demo-
graphics, disease characteristics and prior anticholin-
ergic therapy profiles were balanced between the
treatment groups (Table 1).
The average age of patients was 60.4 years; 87.8%
were females. The mean duration of OAB was
6.1 years, and patients reported an average of 5.4 UI
episodes/day. Patients had used an average of 2.4 an-
ticholinergics prior to study entry; 34.5% (378/1097)
of patients had previously used one anticholinergic
therapy, 27.0% (296/1097) had used two and 38.6%
(423/1097) had used three or more anticholinergic
therapies. The mean duration of prior anticholinergic
use was approximately 2.3 years (Table 1).
Overall, 3407 unique regimens of anticholinergic
therapies were taken by all patients prior to study
enrolment. The majority (82.2%) of these therapies
provided insufficient efficacy. For 70.2% of patients,
insufficient efficacy was the primary reason for inad-
equate management by all of their prior anticholiner-
gic therapies, for 10.3% of patients, the primary
reason was intolerable side effects, and 19.2% of
patients discontinued at least one anticholinergic for
inadequate efficacy and at least one anticholinergic
for intolerable side effects (Table 1). The primary
reason for inadequate management by the first anti-
cholinergic was used for analysis.
Efficacy outcomes
Overall pooled population
Treatment with onabotulinumtoxinA 100U resulted
in significant reductions from baseline in daily UI
episodes at week 12 compared with placebo (2.80
vs. 0.95 episodes/day; p < 0.001) (Figure 1A). Sig-
nificantly higher proportions of onabotulinumtoxinA-
than placebo-treated patients demonstrated a
≥ 50% reduction from baseline in UI episodes
(60.5% vs. 31.0%; p < 0.001) and became continent
(100% reduction in UI episodes; 27.1% vs. 8.4%;
p < 0.001) (Figure 1B). At week 12, a significantly
greater proportion of onabotulinumtoxinA-treated
patients achieved a positive response on the TBS
compared with placebo (61.8% vs. 28.0%;
p < 0.001) (Figure 2).
Improvements were also demonstrated in other
OAB symptoms following treatment with onabotuli-
numtoxinA compared with placebo, with significant
reductions from baseline at week 12 in the average
daily episodes of urgency (3.30 vs. 1.23;
p < 0.001) (Figure 3A) and micturition (2.35 vs.
0.87; p < 0.001) (Figure 3B).
The duration of treatment effect (median time to
qualification for retreatment) was 24 weeks following
treatment with onabotulinumtoxinA compared with
13 weeks with placebo. Retreatment could occur
from 12 weeks onward, thus, the placebo-treated
patients requested/received retreatment shortly after
it was permitted.
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Subgroup of patients by number of prior
anticholinergics used (1, 2 and ≥ 3)
As in the overall pooled population, significant and
meaningful reductions from baseline in daily UI epi-
sodes were observed with onabotulinumtoxinA com-
pared with placebo regardless of the number of prior
anticholinergics used. At week 12, mean reductions
were 2.82 vs. 1.52 for the subgroup with one
prior anticholinergic, 2.58 vs. 0.58 for those with
two prior anticholinergics and 2.92 vs. 0.73 for
the three or more anticholinergics subgroup
(p < 0.001 vs. placebo for all) (Figure 1A).
These results were reflected in the patient percep-
tion of benefit with 69.0%, 58.8% and 56.4% of
onabotulinumtoxinA-treated patients with one, two
and three or more prior anticholinergics, respec-
tively, reporting a positive TBS response, compared
with only 37.2%, 24.8% and 22.5% of patients in the
respective placebo groups (p < 0.001 vs. placebo for
all) (Figure 2).
Significant reductions, comparable with the overall
pooled population, were also observed in the OAB
symptoms of urgency and micturition in onabotuli-
numtoxinA- vs. placebo-treated patients, regardless
of the number of prior anticholinergic therapies
used. Reductions from baseline in average daily
episodes of urgency with onabotulinumtoxinA com-
pared with placebo were 3.63 vs. 1.97 for patients
with one prior anticholinergic, 3.37 vs. 0.82 for
those with two prior anticholinergics and 2.90 vs.
0.93 for patients with three or more prior anticho-
linergics (p < 0.001 vs. placebo for all) (Figure 3A).
Reductions from baseline in mean daily episodes of
micturition were 2.70 vs. 1.45 for the subgroup
with one prior anticholinergic, 2.41 vs. 0.71 for
those with two prior anticholinergics and 1.93 vs.
0.52 for patients with three or more prior anticho-
linergics (p < 0.001 vs. placebo for all) (Figure 3B).
Subgroup of patients by reasons for inadequate
management by anticholinergic therapy
(inadequate efficacy and intolerant side effects)
OnabotulinumtoxinA significantly reduced UI epi-
sodes from baseline compared with placebo at week
12, regardless of the reason for inadequate manage-
ment of OAB by anticholinergic therapy. Reductions
from baseline were 2.80 vs. 0.99 episodes/day in
the onabotulinumtoxinA and placebo groups, respec-
tively, for patients with insufficient efficacy
(p < 0.001) and 2.68 vs. 0.71 episodes/day for
those with intolerable side effects (p < 0.05) (Fig-
ure 1A).
Table 1 Baseline demographics, disease characteristics and ACH profile (overall pooled ITT population)
Characteristic Placebo (n = 548) OnabotA 100U (n = 557) Overall (N = 1105)
Age (years) 60.1  13.6 60.6  14.2 60.4  13.9
Female gender, n (%) 474 (86.5) 496 (89.0) 970 (87.8)
Duration of OAB (years) 6.1  7.1 6.0  7.1 6.1  7.1
Daily UI episodes 5.4  3.6 5.5  3.7 5.4  3.6
Daily urgency episodes 8.3  4.1 8.8  4.7 8.6  4.4
Daily micturition episodes 11.5  3.4 12.0  4.1 11.7  3.9
PVR urine volume (ml) 19.5  24.7 22.5  27.4 21.0  26.1
Number of prior ACH therapies used by patients
Overall mean number 2.5 2.4 2.4
1 ACH therapy, n/N (%) 176/545 (32.3) 202/552 (36.6) 378/1097* (34.5)
2 ACH therapies, n/N (%) 145/545 (26.6) 151/552 (27.4) 296/1097* (27.0)
≥ 3 ACH therapies, n/N (%) 224/545 (41.1) 199/552 (36.1) 423/1097* (38.6)
Mean duration of ACH use (years) 2.2 2.4 2.3
Reason for inadequate management of OAB by ACH therapies
Overall unique regimens of ACH therapies across all patients, n/N (%)
Insufficient efficacy 1273/1576 (80.8) 1233/1471 (83.8) 2506/3047 (82.2)
Side effects 303/1576 (19.2) 238/1471 (16.2) 541/3047 (17.8)
Number of patients inadequately managed by ACH therapies, n/N (%)
Only insufficient efficacy 372/547 (68.0) 402/555 (72.4) 774/1102† (70.2)
Only side effects 56/547 (10.2) 58/555 (10.5) 114/1102† (10.3)
Both‡ (insufficient efficacy and side effects) 119/547 (21.8) 93/555 (16.8) 212/1102† (19.2)
Data are mean  SD unless otherwise indicated. *Eight patients had missing information regarding prior ACH use. †Three patients had
missing information regarding reason for discontinuation of ACH therapy. ‡Patients who had discontinued at least one ACH for
inadequate efficacy and at least one ACH for intolerable side effects. ACH, anticholinergic; ITT, intent-to-treat; OAB, overactive bladder;
onabotA, onabotulinumtoxinA; PVR, postvoid residual.
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A significantly higher proportion of patients with
insufficient efficacy reported a positive response on
the TBS following treatment with onabotulinumtox-
inA 100U compared with placebo (60.7% vs. 27.5%;
p < 0.001). Similarly, the proportion of TBS
responders was higher in the onabotulinumtoxinA
(B)
(A)
Figure 1 (A) Change from baseline in daily average UI episodes at week 12 in the overall pooled population and
subgroups, and (B) proportion of patients achieving ≥ 50% or 100% reduction from baseline in UI episodes at week 12 in
the overall pooled population. Error bars are 95%  CI. *p < 0.001; †p < 0.05 vs. placebo. ACH, anticholinergic; CI,
confidence interval; onabotA, onabotulinumtoxinA; UI, urinary incontinence.
Figure 2 Proportion of patients with a positive response (their condition ‘greatly improved’ or ‘improved’) on the
treatment benefit scale at week 12 in the overall pooled population and subgroups. Error bars are 95%  CI. *p < 0.001
vs. placebo. ACH, anticholinergic; CI, confidence interval; onabotA, onabotulinumtoxinA.
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group compared with placebo in the subgroup of
patients with intolerable side effects (65.6% vs.
29.2%; p < 0.001) (Figure 2).
Overactive bladder symptoms of urgency and mic-
turition were significantly reduced with onabotuli-
numtoxinA treatment compared with placebo,
regardless of the reason for inadequate management
of OAB. At week 12, reductions from baseline in
mean daily episodes of urgency were 3.19 vs. 1.28
for patients with insufficient efficacy (p < 0.001) and
3.71 vs. 0.98 (p < 0.05) for those with intolerable
side effects (Figure 3A). Reductions from baseline in
mean daily episodes of micturition were 2.31 vs.
0.88 (p < 0.001) in patients with insufficient effi-
cacy and 2.51 vs. 0.77 (p < 0.05) in those with
intolerable side effects (Figure 3B). These reductions
in the episodes of urgency and micturition frequency
were comparable with the results observed in the
pooled population (Figure 3A and B).
Safety outcomes
The most common AEs were localised urologic
events. UTI was the most frequently reported AE
in the pooled safety population (25.5% with onab-
otulinumtoxinA vs. 9.6% with placebo) (Table 2)
and all but one case of UTI was uncomplicated;
one case of pyelonephritis was reported in the on-
abotulinumtoxinA group. Other AEs of note that
occurred at a higher incidence with onabotulinum-
toxinA than placebo at any time in treatment cycle
1 were dysuria (10.9% vs. 7.0%), bacteriuria (8.0%
vs. 3.5%) and urinary retention (5.8% vs. 0.4%).
There were no clinically relevant differences in the
incidence of AEs in the pooled population and the
subgroups.
The majority of patients in both the onabotuli-
numtoxinA (82.3%) and placebo group (95.7%) had
a PVR urine volume of ≤ 100 ml at week 12 in treat-
ment cycle 1 (Table 3).
In the pooled safety population, the proportion of
patients who initiated CIC at any time in treatment
cycle 1 was low: 6.5% (36/552) in the onabotulinum-
toxinA 100U group vs. 0.4% (2/542) in the placebo
group (Table 3). Following treatment with onabotul-
inumtoxinA, 2.5% (14/552) of the patients used CIC
for ≤ 6 weeks, and 2.7% (15/552) used CIC for
> 12 weeks (Figure 4). Nearly all patients in the
onabotulinumtoxinA group (20/21; 95.2%) in the
(A)
(B)
Figure 3 Change from baseline in daily average episodes of (A) urgency and (B) micturition at week 12 in the overall
pooled population and subgroups. Error bars are 95%  CI. *p < 0.001; †p < 0.05 vs. placebo. ACH, anticholinergic; CI,
confidence interval; onabotA, onabotulinumtoxinA.
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overall pooled population who had a PVR urine vol-
ume ≥ 350 ml initiated CIC, while 13/38 patients
(34.2%) with PVR urine volumes between 200 and
< 350 ml initiated CIC (Table 3).
Similar to the overall pooled safety population, the
rates of CIC initiation were low in the subgroup by
number of prior anticholinergics and reason for dis-
continuation of anticholinergics (Table 3).
Study discontinuation rates due to AEs were low
in the overall pooled safety population: 1.4% in the
onabotulinumtoxinA group and 1.7% in the placebo
group; comparable rates of discontinuations due to
AEs were observed in the subgroups (Table 2). Over-
all, two deaths, both unrelated to treatment, were
reported during treatment cycle 1. One patient in the
placebo group died due to diverticulitis and pneu-
mothorax and another patient treated with onabotul-
inumtoxinA 100U died of an acute myocardial
infarction.
Discussion
This prespecified pooled analysis of two phase 3,
randomised, placebo-controlled trials in OAB
patients with UI demonstrates that regardless of the
number of prior anticholinergic medications used or
the reasons for inadequate management of OAB,
onabotulinumtoxinA 100U provides significant and
clinically meaningful improvements in the symptoms
of OAB, including episodes of incontinence, urgency
and micturition. These findings are clinically rele-
vant, particularly since the persistence rates for anti-
cholinergic therapy are low (16–18), and as many as
70% of OAB patients discontinue treatment within a
year of initiation either due to insufficient efficacy or
intolerable side effects (9–12).
There is limited information on the benefits of
switching to another anticholinergic agent after prior
treatment failure, and the few studies that have
reported efficacy after switching were open-label,
non-randomised trials and thus were subject to
patient and physician bias (19,20). Furthermore, a
recent study showed that patients treated with a sin-
gle injection of onabotulinumtoxinA 100U were
twice as likely as those receiving an anticholinergic
regimen (that allowed for dose escalation and switch-
ing of anticholinergic therapy) to report complete
resolution of UUI episodes (21).
Findings in our analysis demonstrate that onabo-
tulinumtoxinA is an effective alternative in OAB
patients after failing treatment with just one anticho-
linergic agent. Hence, these results may have impor-
tant implications for clinical practice and help
physicians make informed decisions about second-
line treatment options for their patients.
Furthermore, onabotulinumtoxinA was similarly
effective in patients who discontinued prior anticho-
linergic therapy due to inadequate efficacy or intoler-
able side effects. In contrast to our results, a small,
retrospective study reported that patients who were
intolerant to anticholinergic side effects had a more
successful treatment response to onabotulinumtoxin-
A than those who had inadequate efficacy (22).
However, the treatment success reported in the retro-
spective study may be subject to response bias, as it
was solely based on patient satisfaction and did not
consider objective efficacy assessments.
Results of the subgroup analyses of patients by
number of prior anticholinergics and reasons for dis-
continuation of anticholinergics were similar to the
significant and clinically relevant improvements seen
in the overall pooled population. This is notable
Figure 4 Duration of CIC in the pooled safety population. CIC was initiated when PVR ≥ 350 ml, or if PVR ≥ 200 ml
and < 350 ml and patient had associated symptoms assessed by the investigator to require CIC, or when PVR ≥ 350 ml
regardless of symptoms. CIC, clean intermittent catheterisation; PVR, postvoid residual.
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since it demonstrates that regardless of the number
of anticholinergics failed or the reason for failure,
patients have the potential to benefit from onabotuli-
numtoxinA therapy, with significant improvements
in OAB symptoms.
Some studies have shown that among symptoms
of OAB, urgency appears to have the greatest
negative impact on patients’ health-related quality of
life (7), and thus has been described as the core
symptom of OAB (23,24). Urgency was the strongest
predictor of OAB-associated bother and patients with
urgency were more likely to have worse scores on
health-related quality of life, anxiety and depression
assessments than patients without urgency (25). In
this analysis, treatment with onabotulinumtoxinA
significantly reduced the number of urgency epi-
sodes in all groups that were studied. The improve-
ments noted in urgency and other OAB symptoms
corresponded to the patient perception of treatment
benefit, with as many as 60–70% of the patients
reporting a significant improvement in their
condition following treatment with onabotulinum-
toxinA, both in the subgroups and the pooled
population.
The robust efficacy of onabotulinumtoxinA could
be attributed to dual efferent and afferent inhibitory
effects on pathways of bladder control. By directly
inhibiting the efferent acetylcholine-mediated detru-
sor contractions, onabotulinumtoxinA contributes to
the reductions in leakage due to episodes of inconti-
nence. In addition, injection of onabotulinumtoxinA
into the bladder wall decreases the mucosal levels of
the afferent neuronal receptors TRPV1 and P2X3,
which are important in sensory feedback (26–29),
and may decrease the levels of afferent neurotrans-
mitters relevant to the sensation of urgency. Thus,
the current notion is that onabotulinumtoxinA mod-
ulates the intrinsic reflexes thought to cause the OAB
condition and improves the associated symptoms of
OAB, including the most bothersome symptom of
urgency.
The duration of treatment effect (median time to
qualification for retreatment) with onabotulinum-
toxinA was significantly longer compared with pla-
cebo (24 vs. 13 weeks, respectively). An interim
analysis of an ongoing study of repeated treatments
with onabotulinumtoxinA showed sustained and
consistent improvements in OAB symptoms,
patients’ perception of improvement in their condi-
tion and health-related quality of life (30). Taken
together, these results suggest that onabotulinumtox-
inA could potentially maximise the chance of treat-
ment success and long-term adherence to therapy in
OAB patients who are inadequately managed by anti-
cholinergics. These results are noteworthy consider-
ing that the majority of OAB patients discontinue
anticholinergic therapy in a median of < 20 weeks of
starting treatment (11).
The pooled safety results confirm those observed
in the individual phase 3 trials (13,14), indicating
that onabotulinumtoxinA was well tolerated, with
most of the AEs localised to the urinary tract. In
addition, there were no clinically relevant differences
in the incidence of AEs between the subgroups and
the pooled population. Although onabotulinum-
toxinA was associated with an increase in PVR urine
volume in all groups, the clinical consequence of this
increase was limited, as the rates of urinary retention
(range: 3.5–7.9%) and initiation of CIC were low
(range: 4.0–8.5%) in all groups. In nearly 40% of the
patients who did initiate CIC following treatment
with onabotulinumtoxinA, the duration of CIC was
≤ 6 weeks.
One limitation of this analysis is the small sample
size of the subgroups, particularly those who discon-
tinued prior anticholinergic therapy because of side
effects, and hence the results, including the low rates
of urinary retention, should be interpreted accord-
ingly. In addition, the reasons for discontinuation of
prior anticholinergic therapies recorded at study en-
rolment were patient-reported responses and thus
were subjective in nature.
Conclusions
In this pooled analysis of OAB patients with UI who
were inadequately managed with anticholinergics,
onabotulinumtoxinA 100U provided significant
reductions in UI episodes and improvements in all
evaluated symptoms of OAB, including urgency,
which were reflected in patients’ perception of treat-
ment benefit. Similar improvements were observed
in subgroups of OAB patients with UI, regardless of
the number of prior anticholinergics used or reasons
for inadequate management of OAB. Onabotulinum-
toxinA was well tolerated, with a safety profile that is
consistent with the individual phase 3 trials. The
results of this study suggest that onabotulinumtoxinA
is an effective and appropriate alternative in OAB
patients with UI after failing treatment with one
or more anticholinergic.
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